Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
ADMETox, Alex, Alexander, amplify, antimicrobial, APEXTM, AppliskanTM, assay, Athena, Australian, Bell, BioImage, Bioreactor, Canada, Cardinal, CB, CombiTM, confirmation, conventional, crystalline, DarwinTM, diffraction, DiscoveryTM, DXR, ELISA, entity, enzyme, exciting, FlashTM, FleetTM, FluoroskanTM, formation, GCTM, gene, Georgia, German, GlaxoSmithKline, guidance, HybaidTM, ideal, incubation, infection, irrevocable, Kaufman, kinetic, KingFisherTM, KRILPROTM, likelihood, luminometer, LuminoskanTM, microbial, microscopy, modulate, Multidrop, multimode, MultiskanTM, Mumbai, NanoDrop, Nanogen, NautilusTM, NE, neurological, noncontrolling, nonmonetary, OmniTM, Oryx, pocket, proposed, pump, QPCR, QSPTM, QuantoDesk, quarry, rata, receipt, recipient, renal, robust, SampleManagerTM, scalability, sealing, solid, spectrophotometry, statute, synthetic, tank, therapy, TLP, twelve, UHPLC, unattended, Union, Varioskan, VersaWeigh, VTM, washer, WEEE, winning
Removed:
AB, abuse, AC, advisory, aggregated, auger, beam, Counseling, diffractometry, downturn, epitaxy, expenditure, Graseby, grew, headcount, InnaPhase, intention, liquidate, microspectroscopy, mixture, nearest, noncash, noncurrent, nonoperating, nonqualified, NW, photoelectron, publicly, reclassification, refunded, replaced, restoration, Saturday, simplify, sized, spectra, spinning, spun, subsidiary, ThermoLase, ThermoQuest, VG
Filing tables
Filing exhibits
- 10-K Annual report
- PDF TMO 10-K 2007 (PDF Version)
- 3.3 TMO 10-K 2007 Exhibit 3.3 (Bylaws of the Company)
- 10.70 TMO 10-K Exhibit 10.70 (Executive Change In Control Retention Agreement)
- 10.71 TMO 10-K 2007 Exhibit 10.71 (Fsii Severance Plan for Key Employees)
- 10.72 TMO 10-K 2007 Exhibit 10.72 (Notice of Participation - Alex Stachtiaris)
- 10.73 TMO 10-K 2007 Exhibit 10.73 (Notice of Participation - Alan Malus)
- 10.74 TMO 10-K 2007 Exhibit 10.74 (Letter Agreement with Alan Malus)
- 10.75 TMO 10-K 2007 Exhibit 10.75 (Description of Amendments)
- 10.76 TMO 10-K 2007 Exhibit 10.76 (Amendment to Equity Incentive Plan)
- 10.77 TMO 10-K 2007 Exhibit 10.77 (Amendment to Employees Equity Incentive Plan)
- 10.78 TMO 10-K 2007 Exhibit 10.78 (Amendment to Directors Stock Option Plan)
- 10.79 TMO 10-K 2007 Exhibit 10.79 (Amendment to 2005 Stock Incentive Plan)
- 10.80 TMO 10-K 2007 Exhibit 10.80 (Amendment to 2005 Equity and Incentive Plan)
- 10.81 TMO 10-K 2007 Exhibit 10.81 (Amendment to 2001 Equity Incentive Plan)
- 21 TMO 10-K 2007 Exhibit 21 (Subsidiaries of the Registrant)
- 23.1 Tmmo 10-K 2007 Exhibit 23.1 (PWC Consent)
- 31.1 TMO 10-K 2007 Exhibit 31.1 (Certification)
- 31.2 TMO 10-K 2007 Exhibit 31.2 (Certification)
- 32.1 TMO 10-K 2007 Exhibit 32.1 (Certification)
- 32.2 TMO 10-K 2007 Exhibit 32.2 (Certification)
Related press release
TMO similar filings
Filing view
External links
Exhibit 10.75
Amendments to Certain Stock Option Plans
Effective February 27, 2008, all stock option plans of Thermo Fisher Scientific Inc. (the “Company”) with stock options outstanding thereunder but pursuant to which additional stock options may no longer be granted, and all stock option plans of the Company’s former subsidiaries assumed by the Company, that did not already include the following provision were amended to provide that unless such action is approved by the Company’s stockholders: (1) no outstanding option granted under the relevant plan may be amended to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding option (other than adjustments in the event of certain extraordinary transactions) and (2) the Board may not cancel any outstanding option (whether or not granted under the relevant plan) and grant in substitution therefor new awards under the relevant plan covering the same or a different number of shares of common stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled option.